WhatsApp
backNews Article

TTK Healthcare to Issue Rs.706.52 Crore Bonus Non-Convertible Redeemable Preference Shares with 9.5% Dividend

Scheme approved for issuance of 5 NCRPS for every equity share, redeemable within 15 months and proposed listing on BSE and NSE

TTK Healthcare Limited's Board approved a Scheme for issuing 7,06,51,665 Non-Convertible Redeemable Preference Shares worth Rs.706.52 crores as bonus to equity shareholders, at a ratio of 5 NCRPS per equity share. The preference shares carry a 9.5% annual dividend and a 15-month tenure with redemption options.

18 hours ago|TTKHLTCARE+0.00%
TTK Healthcare Limited507747TTKHLTCAREAcquisition / Amalgamation / Merger / Demerger

TTK Healthcare Limited

Acquisition / Amalgamation / Merger / Demerger

TTK Healthcare Limited's Board approved a Scheme of Arrangement to issue 7,06,51,665 Non-Convertible Redeemable Preference Shares (NCRPS) as a bonus to its equity shareholders, at a ratio of 5 NCRPS per equity share held as on record date. These NCRPS have a face value of Rs.100 each and carry an annual dividend rate of 9.5% with a redemption tenure of 15 months.

The bonus issue will utilize the company’s reserves or retained earnings to allot NCRPS valued at Rs.706.52 crores. The dividend accrues from allotment date up to March 31 of the financial year, and thereafter on each March 31 until redemption.

Redemption of the NCRPS will be at par after 15 months from allotment or earlier at the Board’s option. The shares are proposed to be listed on both BSE Limited and National Stock Exchange of India Limited.

This issuance follows approvals required from statutory, regulatory authorities, including National Company Law Tribunal (NCLT), stock exchanges, shareholders, and creditors as applicable.

Pre-bonus, TTK Healthcare's total issued equity share capital stands at Rs.14.13 crores (1.41 crore shares of Rs.10 each). Post issuance, the company’s authorised share capital increases to Rs.7,50,00,00,000 including 7.3 crore NCRPS and equity share capital remains unchanged.

The Scheme document will be available on the company’s website after filing with stock exchanges.

Highlights

  • Bonus issue ratio: 5 NCRPS of Rs.100 each for every 1 equity share of Rs.10
  • Total NCRPS to be issued: 7,06,51,665 shares amounting to Rs.706.52 crores
  • Dividend rate fixed at 9.5% per annum, accruing annually with first accrual from allotment date
  • Tenure of NCRPS: 15 months with option for earlier redemption by Board
  • Proposed listing on BSE and NSE
  • Funding through utilization of general reserves and/or retained earnings as per September 30, 2026 figures

Key Data Snapshot

Type of InstrumentNon-Convertible Redeemable Preference Shares (NCRPS)
Bonus Ratio5 NCRPS of Rs.100 each for every 1 equity share of Rs.10
Total NCRPS Issued7,06,51,665 NCRPS
Total Issue SizeRs.706.52 crores
Dividend Rate9.5% per annum
Tenure15 months from allotment date
Face Value per NCRPSRs.100
Issue Price per NCRPSRs.100 (Face value)
Pre-Bonus Equity Share Capital1,41,30,333 equity shares of Rs.10 each totaling Rs.14,13,03,330
Post-Bonus Authorised Share CapitalRs.7,50,00,00,000 comprising 2 crore equity shares and 7.3 crore NCRPS
Record Date StatusTo be determined pursuant to the Scheme

What happened

  • TTK Healthcare's Board approved a Scheme for issuance of NCRPS by way of bonus to its equity shareholders.
  • The issuance is on a 5:1 ratio of NCRPS per equity share held as on the record date.
  • NCRPS carry a 9.5% annual dividend and a 15-month redemption tenure, redeemable earlier at the Board's discretion.

Key details

  • Total number of NCRPS issued: 7,06,51,665 amounting to Rs.706.52 crores.
  • Dividend accrual from allotment to March 31 of the financial year, thereafter annually.
  • NCRPS to be listed on BSE and NSE, the same exchanges where equity shares are listed.
  • Funding will use general reserves and/or retained earnings as of September 30, 2026.
  • Pre-bonus equity shares total 1,41,30,333 with Rs.14.13 crores paid-up capital.
  • Post-bonus authorised share capital increases to Rs.7,50,00,00,000.

Regulatory and governance context

  • The Scheme is subject to approvals from National Company Law Tribunal (NCLT), stock exchanges, shareholders, and creditors as required.
  • Details of the Scheme will be made available on the company website after stock exchange filing.
  • The issuance aligns with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
  • Financial figures related to reserves and earnings are based on limited reviewed results as of September 30, 2026.

More News on Acquisition / Amalgamation / Merger / Demerger

View all

Latest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.

View all news
TTK Healthcare to Issue Rs.706.52 Crore Bonus…